Altimmune, Inc. (ALT)
2.585
-0.08
(-2.82%)
USD |
NASDAQ |
Oct 08, 10:51
Altimmune Net Income (Quarterly) : -22.82M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -22.82M |
| March 31, 2026 | -22.56M |
| December 31, 2025 | -27.36M |
| September 30, 2025 | -19.01M |
| June 30, 2025 | -22.15M |
| March 31, 2025 | -19.58M |
| December 31, 2024 | -23.18M |
| September 30, 2024 | -22.84M |
| June 30, 2024 | -24.64M |
| March 31, 2024 | -24.39M |
| December 31, 2023 | -31.64M |
| September 30, 2023 | -20.67M |
| June 30, 2023 | -16.06M |
| March 31, 2023 | -20.07M |
| December 31, 2022 | -21.66M |
| September 30, 2022 | -23.52M |
| June 30, 2022 | -20.11M |
| March 31, 2022 | -19.43M |
| December 31, 2021 | -23.89M |
| September 30, 2021 | -33.51M |
| June 30, 2021 | -24.83M |
| March 31, 2021 | -14.86M |
| December 31, 2020 | -10.62M |
| September 30, 2020 | -17.77M |
| June 30, 2020 | -16.77M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.886M |
| December 31, 2019 | -4.097M |
| September 30, 2019 | -10.94M |
| June 30, 2019 | -3.387M |
| March 31, 2019 | -2.097M |
| December 31, 2018 | -24.51M |
| September 30, 2018 | -2.351M |
| June 30, 2018 | -9.139M |
| March 31, 2018 | -3.174M |
| December 31, 2017 | -8.831M |
| September 30, 2017 | -29.91M |
| June 30, 2017 | -3.155M |
| March 31, 2017 | -4.579M |
| December 31, 2016 | -3.062M |
| September 30, 2016 | -4.795M |
| June 30, 2016 | -1.704M |
| March 31, 2016 | -1.227M |
| December 31, 2015 | -1.238M |
| September 30, 2015 | -1.325M |
| June 30, 2015 | -2.341M |
| March 31, 2015 | 1.463M |
| December 31, 2014 | -2.629M |
| September 30, 2014 | -4.628M |
| June 30, 2014 | -0.4391M |
| March 31, 2014 | -2.258M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Protalix Biotherapeutics, Inc. | 3.777M |
| Taysha Gene Therapies, Inc. | -46.64M |
| Humacyte, Inc. | -36.80M |
| Liquidia Corp. | 74.72M |
| Agenus, Inc. | -0.567M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 22.82M |
| EPS Diluted (Quarterly) | -0.1231 |
| Enterprise Value | 227.00M |
| Earnings Yield | -30.52% |
| Normalized Earnings Yield | -30.40 |